RBC Capital Maintains Outperform on Neurocrine Biosciences, Raises Price Target to $190
Benzinga Newsdesk 4 hours ago
Analyst RatingsNewsPrice Target
RBC Capital analyst Brian Abrahams maintains Neurocrine Biosciences (NASDAQ:NBIX) with a Outperform and raises the price target from $187 to $190.
RBC Capital analyst Brian Abrahams maintains Neurocrine Biosciences (NASDAQ:NBIX) with a Outperform and raises the price target from $187 to $190.